Antengene Corporation Limited
德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2021

The board of directors (the "**Board**") of Antengene Corporation Limited (the "**Company**" or "**Antengene**") is pleased to announce the consolidated results of the Company and its subsidiaries (together, the "**Group**", "**we**" or "**us**") for the year ended December 31, 2021 (the "**Reporting Period**"), together with comparative figures for the year ended December 31, 2020. The consolidated financial statements of the Group for the Reporting Period have been reviewed by the Audit Committee of the Company and audited by the Company's auditor.

FINANCIAL HIGHLIGHTS

	Year ended December 31,	
	2021	2020
	RMB'000	*RMB'000*
Revenue	**28,769**	–
Other income and gains	**42,567**	26,834
Research and development costs	**(405,029)**	(347,655)
Selling and distribution expenses	**(67,941)**	(455)
Administrative expenses	**(169,463)**	(154,221)
Fair value loss on convertible redeemable preferred shares*	**–**	(2,356,271)
Loss for the year	**(655,529)**	(2,928,921)
Total comprehensive loss for the year	**(639,490)**	(2,928,921)
Adjusted loss for the year**	**(613,444)**	(454,958)

* This represents the loss on the fair value changes of convertible redeemable preferred shares, a non-cash and one-time adjustment recognized upon listing as required under the International Financial Reporting Standards ("**IFRSs**").

** Adjusted loss for the year is not defined under the IFRS, it represents the loss for the year excluding the effect brought by equity-settled share option expense, share issue expenses and fair value loss on convertible redeemable preferred shares.

IFRS Measures:

Our revenue increased from nil for the year ended December 31, 2020 to RMB28.8 million for the year ended December 31, 2021, primarily attributable to the increase in revenue from our Named Patient Program.

Our other income and gains increased by RMB15.8 million from RMB26.8 million for the year ended December 31, 2020 to RMB42.6 million for the year ended December 31, 2021, primarily attributable to the increase in government grants and bank interest income.

Our research and development costs increased by RMB57.3 million from RMB347.7 million for the year ended December 31, 2020 to RMB405.0 million for the year ended December 31, 2021, primarily attributable to our increased drug development expenses and expansion of R&D personnel, which was partially offset by our decreased licensing fees and equity-settled share option expense.

Our selling and distribution expenses increased by RMB67.4 million from RMB0.5 million for the year ended December 31, 2020 to RMB67.9 million for the year ended December 31, 2021, primarily attributable to the increase in employee costs and professional fees incurred for activities associated with marketing and sales related to preparations to commercialize our lead product, selinexor, in Greater China, and other countries/regions.

Our administrative expenses increased by RMB15.3 million from RMB154.2 million for the year ended December 31, 2020 to RMB169.5 million for the year ended December 31, 2021, primarily attributable to our increased professional fees and expansion of administrative personnel, which was partially offset by our decreased listing expenses and equity-settled share option expense.

Fair value loss on convertible redeemable preferred shares decreased from RMB2,356.3 million for the year ended December 31, 2020 to nil for the year ended December 31, 2021, as the Group had no preferred shares outstanding as at December 31, 2021.

The loss for the year decreased by RMB2,273.4 million from RMB2,928.9 million for the year ended December 31, 2020 to RMB655.5 million for the year ended December 31, 2021, primarily attributable to the decrease in the fair value loss on convertible redeemable preferred shares of RMB2,356.3 million.

Non-IFRS Measures:

Research and development costs excluding the equity-settled share option expense increased by RMB79.0 million from RMB303.7 million for the year ended December 31, 2020 to RMB382.7 million for the year ended December 31, 2021, primarily attributable to our increased drug development expenses and expansion of R&D personnel, which was partially offset by our decreased licensing fees.

Selling and distribution expenses excluding the equity-settled share option expense increased by RMB65.4 million from RMB0.5 million for the year ended December 31, 2020 to RMB65.9 million for the year ended December 31, 2021, primarily attributable to the increase in employee costs and professional fees incurred for activities associated with marketing and sales related to preparations to commercialize our lead product, selinexor, in Greater China, and other countries/regions.

Administrative expenses excluding the equity-settled share option expense and share issue expenses increased by RMB71.2 million from RMB80.5 million for the year ended December 31, 2020 to RMB151.7 million for the year ended December 31, 2021, primarily attributable to the increase in employee costs and professional fees.

Loss for the year excluding the effect brought by equity-settled share option expense, share issue expenses and fair value loss on convertible redeemable preferred shares increased by RMB158.4 million from RMB455.0 million for the year ended December 31, 2020 to RMB613.4 million for the year ended December 31, 2021, primarily due to the increase in administrative expenses, research and development costs and selling and distribution expenses.

BUSINESS HIGHLIGHTS

During the year ended December 31, 2021, and as at the date of this announcement, significant advancement has been made with respect to our product pipeline and business operations:

Late-stage assets:

- **Selinexor (ATG-010, XPOVIO®, Greater China brand name 希維奧®, first-in-class XPO1 inhibitor)**

  - In January 2021, we received the approval of the investigational new drug ("**IND**") application by the National Medical Products Administration ("**NMPA**") for selinexor in combination with rituximab, gemcitabine, dexamethasone and platinum ("**SR-GDP**") for the treatment of relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) in a global Phase II/III study (the "**XPORT-DLBCL-030 trial**") and we dosed the first patient in China in December 2021.

  - In January 2021, the NMPA accepted the New Drug Application ("**NDA**") for ATG-010 (Selinexor, XPOVIO®), a first-in-class oral selective inhibitor of nuclear export (SINE) compound, for the treatment of patients with relapsed/refractory multiple myeloma (rrMM). On February 24, 2021, the NMPA granted priority review to the NDA for ATG-010.

  - In May 2021, we received the approval of IND application by NMPA for a Phase III clinical trial designed to evaluate the safety and efficacy of selinexor as a maintenance therapy for patients with advanced or recurrent endometrial cancer (the "**SIENDO trial**") and we dosed the first patient in China in November 2021.

  - In May 2021, multiple selinexor (ATG-010) regimens were added by Chinese Society of Clinical Oncology (CSCO) to its 2021 Diagnosis and Treatment Guidelines (CSCO Guidelines) for treatment of multiple myeloma and lymphoma. Three selinexor regimens recommended by the Guideline for the Diagnosis and Treatment of myeloma include: (i) selinexor plus dexamethasone; (ii) selinexor plus dexamethasone plus bortezomib; and (iii) selinexor plus dexamethasone plus pomalidomide for the treatment of relapsed myeloma. Meanwhile, the guideline has also recommended selinexor for the treatment of rrDLBCL.

  - In June 2021, we announced that the results from the Phase II MARCH trial of selinexor plus low dose dexamethasone (the Sd regimen) for the treatment of Chinese patients with rrMM had been published at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2021 European Hematology Association (EHA) Virtual Congress. Data from a planned analysis of the first 60 treated patients with a median follow-up of 9.5 months demonstrates an overall response rate (ORR) of 26.7%. Meanwhile, an ORR of 33.3% was achieved with the Sd regimen in triple-class-exposed (IMiDs, PIs and anti-CD38 mAb) patients, and an ORR of 44.4% was achieved in patients that previously received CAR-T therapies. In Chinese patients that were refractory to both immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs), results from the MARCH trial have confirmed the efficacy and manageable safety profile of the Sd regimen, which is consistent with that observed in the STORM trial, the data from which supported the accelerated approval of selinexor by the U.S. Food and Drug Administration ("**FDA**").

- In July 2021, we submitted an NDA to Taiwan Food and Drug Administration ("**TFDA**") for selinexor for three indications: in combination with bortezomib and dexamethasone, or in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma; and as monotherapy in adult patients with relapsed and/or refractory diffuse large B-cell lymphoma, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. This is the sixth NDA for ATG-010 submitted by Antengene, after the five NDAs submitted in Mainland China, Australia, South Korea, Singapore and Hong Kong.

- In July 2021, through a priority review process, the South Korean Ministry of Food and Drug Safety ("**MFDS**") approved the Company's NDA for selinexor, in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody (penta-refractory); and as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma who have received at least two prior lines of treatment. This is the first NDA approval of ATG-010.

- In July 2021, we dosed the first patient in the Phase III study of selinexor in combination with bortezomib and dexamethasone vs. bortezomib and dexamethasone (SVd vs. Vd) in mainland China (the "**BENCH trial**").

- In August 2021, we received the approval of the IND application for a Phase II study designed to evaluate the safety and efficacy of selinexor in the treatment of patients with myelofibrosis in China.

- In October 2021, we received the approval of the IND application by the NMPA for selinexor in combination with ATG-008 (onatasertib) for the treatment of rrDLBCL in a Phase Ib clinical study (the "**MATCH trial**").

- In November 2021, we received the approval of the IND application by the NMPA for selinexor in combination with lenalidomide plus rituximab ("**S-R^2**") for the treatment of relapsed/refractory indolent non-Hodgkin lymphoma ("**rriNHL**") in a Phase I/II clinical study (the "**SWATCH trial**").

- In December 2021, selinexor received conditional approval for marketing by the NMPA, applicable in combination with dexamethasone for the treatment of adults with rrMM who have received prior therapy including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

- In December 2021, we submitted supplemental NDA ("**sNDA**") to MFDS for selinexor in combination with bortezomib and dexamethasone indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

- Additionally, in December 2021, we announced that the results from the Phase Ib TOUCH trial of selinexor plus gemcitabine-oxaliplatin ("**GemOx**") for the treatment of Chinese patients with for the treatment of relapsed/refractory (R/R) T and NK-Cell lymphoma are published at the 2021 American Society of Hematology (ASH) Annual Meeting. Data from a planned analysis of the first 26 treated patients demonstrates an overall response rate (ORR) of 46.2%, with CR rate (CRR) of 26.9%, and median PFS of 2.7 months (mos). ORR for PTCL-NOS and ENKTL subgroups reached 53.8% and 57.1%, CR of 30.8% and 28.6%, and median PFS of 4.4 mos and 4.7 mos, respectively. Fifty percent pts had ≥3 lines of prior treatment, and 57% pts had prior exposure to a gemcitabine-based regimen.

• **Onatasertib (ATG-008, mTORC1/2 inhibitor)**

- In February 2021, we dosed the first patient in the dose expansion cohort in the Phase I/II study of onatasertib in combination with toripalimab (anti-PD-1 antibody) in mainland China (the "**TORCH-2 trial**").

- In April 2021, we dosed the first patient in the fourth cohort of the Phase II study in patients with hepatocellular carcinoma ("**HCC**") who received at least one line of prior therapy (the "**TORCH trial**").

- In April 2021, we dosed the first patient in a Phase II trial of ATG-008 in patients with advanced solid tumors harboring NFE2L2, STK11, RICTOR and other specific genetic alterations (the "**BUNCH trial**").

Other clinical stage assets:

• **Eltanexor (ATG-016, second generation XPO1 inhibitor)**

In May 2021, we dosed the first patient in the Phase I/II clinical study in patients with high-risk myelodysplastic syndrome ("**MDS**") in mainland China (the "**HATCH trial**").

In May 2021, we received NMPA's approval of IND application of a Phase I/II clinical study in patients with solid tumors in mainland China (the "**REACH trial**") and we dosed the first patient in December 2021.

In June 2021, data with eltanexor was published at the ASCO annual meeting, which showed a bone marrow complete response (mCR) in 7 patients (47%) and a total disease control rate (DCR) of 80%, of the 15 efficacy-evaluable patients with MDS refractory to hypomethylating agents.

In January 2022, China NMPA accepted the IND application for a Phase 1/2 open label study designed to evaluate the safety, tolerability and efficacy of eltanexor in patients with newly diagnosed and relapsed/refractory cancer indications. Chinese sites will only participate in the Part F Phase 2 of this study to investigate eltanexor in high-risk MDS patients.

- **ATG-019 (dual PAK4/NAMPT inhibitor)**

  In April 2021, we received NMPA's approval of IND application in mainland China of a Phase I clinical trial to evaluate safety and tolerability of ATG-019 (monotherapy or combined with niacin ER) in patients with advanced solid tumors or non-Hodgkin's lymphoma (the "**TEACH trial**").

- **ATG-017 (ERK1/2 inhibitor)**

  The dose-escalation study of ATG-017 for the treatment of advanced solid tumors and hematologic malignancies in Australia (the "**ERASER trial**") is ongoing.

- **ATG-101 (PD-L1/4-1BB bispecific antibody)**

  In December 2021, we dosed the first patient in the Phase I clinical study in patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma (B-NHL) (the "**PROBE trial**"). We also obtained IND clearance from the U.S. FDA in October 2021 for the PROBE study. In March 2022, China NMPA approved the IND application for a Phase I study of ATG-101 in China.

- **Pre-clinical stage assets:**

  We made steady progress in our pre-clinical pipeline assets – ATG-037 (CD73 inhibitor), ATG-018 (ATR inhibitor), ATG-022 (Claudin 18.2 antibody-drug conjugate), ATG-012 (KRAS inhibitor), ATG-031 (anti-CD24 monoclonal antibody), ATG-027 (B7H3/PD-L1 bi-specific antibody), ATG-032 (LILRB antibody) and ATG-041 (Axl-Mer inhibitor).

  Additionally, the Bellberry Human Research Ethics Committee (HREC) in Australia approved our clinical trial application of the Phase I trial of ATG-037 in patients with locally advanced or metastatic solid tumors in February 2022. We plan to initiate this trial and start patient enrollment in Australia in the first half of 2022.

Business development and other key activities:

- Leveraging our combinatory and complementary R&D strategy and through our strong R&D capabilities and strategic approach in developing novel therapies, we continue to realize our vision of treating patients beyond borders and improving their lives in discovering, developing and commercializing global first-in-class, only-in-class and/or best-in-class therapies.

- In May 2021, we entered into an exclusive, worldwide license agreement for the development and commercialization of CB-708 (ATG-037), Calithera Biosciences, Inc.'s small molecule inhibitor of CD73. Preclinical data presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting and the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting demonstrated that CB-708 has immune – mediated, single agent activity in syngeneic mouse tumor models. In preclinical studies, CB-708 was well-tolerated and had showed enhanced anti-tumor activity when combined with either an anti-PD-L1 immunotherapy or with chemotherapeutic agents, such as oxaliplatin or doxorubicin. CB-708 has completed GLP toxicology studies and is poised to advance into clinical development.

- In October 2021, we entered into a Research Collaboration and License Option Agreement with LegoChem Biosciences, Inc. ("**LCB**", KOSDAQ: 141080) for new antibody-drug conjugates (ADCs). Under this agreement, the two parties will jointly generate and evaluate ADC candidates using Antengene's antibodies and LCB's next generation ADC technology platform. Antengene will have an exclusive option to license global rights for the development and commercialization of the resulting ADC candidates. When the option is exercised, LCB will be eligible to receive upfront and milestone payments, as well as tiered royalties. In addition, LCB is eligible to receive a prespecified percentage of any sublicensing income received by Antengene.

- In December 2021, we entered into a collaboration with XtalPi Inc, a quantum physics-based, AI-powered drug R&D company with the mission to revolutionize drug discovery and development by improving the speed, scale, novelty and success rate, announced today a long-term R&D collaboration. Under terms of the agreement, XtalPi will utilize its integrated artificial intelligence (AI) research and development (R&D) platform comprised of proprietary cloud-supercomputer-powered in silico tools and its highly efficient wet lab to support Antengene's drug discovery and development programs.

- In December 2021, we entered into a clinical trial collaboration to evaluate the safety, pharmacokinetics and preliminary efficacy of ATG-017 in combination with Bristol Myers Squibb's PD-1 checkpoint inhibitor, Opdivo® (nivolumab). The open-label Phase 1/2 trial will evaluate the investigational combination as a potential treatment option for patients with advanced solid tumors.

- Moving forward, we will focus on our dual engine strategy by pursuing in-house discovery as well as strategic partnerships to accelerate value creation of the Company.

- With the official commercial launch of XPOVIO® (selinexor, ATG-010) in mainland China and expected approvals across multiple APAC markets towards the mid of 2022, Antengene has continued to build up its experienced commercial team across China and the APAC region with plans to grow its commercial organization to up to 200 full time employees in functions including in-house marketing, field force, pricing and market access by the end of 2022.

- In March 2021, the Company has been selected as a constituent stock of the Hang Seng Composite Index (HSCI), according to the quarterly review results of the Hang Seng Family of Indexes. Based on the inclusion, the Company has been selected as an eligible stock in the Shenzhen-Hong Kong Stock Connect, effective from March 15, 2021.

- In May 2021, we hosted an inauguration ceremony for our manufacturing center at the Binhai Life Science and Healthcare Industrial Zone in Shaoxing. The completion of the manufacturing center paves the way for our future production of oral medicines and marks a major milestone in our transition into an innovative biopharmaceutical company with integrated capabilities in discovery, development, manufacturing, and commercialization. At this site, Antengene plans to soon initiate the manufacturing of selinexor, the Company's first commercial product.

- In May 2021, we entered into a framework agreement with the Hangzhou Qiantang New Area Administrative Committee to build a drug discovery and manufacturing center for antibody biologics, in order to meet the Company's growing need for in-house discovery and to support the Company's commercialization roadmap. This project may involve transactions with various entities in land acquisition and the construction of the facility. This project is expected to be funded by the Company's internal resources, local government subsidies and bank loans.

- In September 2021, Antengene has been included in the FTSE Russell, a leading global index provider, has added Antengene to the following indexes of the FTSE Global Index Series ("**GEIS**"), namely the FTSE Global Small Cap Index, the FTSE Global All Cap Index, and the FTSE Global Total Cap Index, following FTSE's most recent semi-annual review. These inclusions have become effective after the market close on September 17, 2021.

- On November 26, 2021, Antengene has been included in the MSCI Global Small Cap Indexes – MSCI China Index constituent stocks according to the latest semi-annual review results of the world's leading index company MSCI. Relevant adjustments were made after the market closes on November 30, 2021.

MANAGEMENT DISCUSSION AND ANALYSIS

OUR VISION

Our vision is to treat patients beyond borders and improve their lives by discovering, developing and commercializing global first-in-class, only-in-class and/or best-in-class therapies.

OVERVIEW

Started operations in 2017, we are a commercial-stage Asia-Pacific ("**APAC**") biopharmaceutical company focused on innovative oncology medicines. We distinguish ourselves through our strong R&D capabilities and strategic approach to developing novel oncology therapies.

We have strategically designed and built a highly selective pipeline of 15 drug assets focused on oncology, including five with APAC rights and ten with global rights. We employ a combinatory and complementary R&D strategy to maximise the potential of our pipeline assets which are synergistic to each other. We have submitted NDAs for selinexor to health authorities in six APAC markets including mainland China, South Korea, Australia, Singapore, Hong Kong, and Taiwan, and have obtained NDA approvals in mainland China, South Korea, Singapore and Australia. We also obtained IND approvals or initiated five additional registrational clinical trials of our lead asset, selinexor, in rrMM, rrDLBCL, endometrial cancer and myelofibrosis in mainland China.

XPOVIO® (selinexor, ATG-010) being a first-in-class and only-in-class orally available XPO1 inhibitor and ATG-008 (onatasertib) being a potentially first-in-class mTORC1/2 inhibitor. Among our clinical stage assets, we also have two other drug candidates in the validated selective inhibitor of nuclear export ("**SINE**") class, namely ATG-016 (eltanexor) and ATG-527 (verdinexor), which feature differentiated profiles that allow us to target a wide range of indications through both mono-and combination therapies. ATG-019 is a potentially first-in-class orally available dual PAK4/NAMPT inhibitor for the treatment of non-Hodgkin lymphoma (NHL) and advanced solid tumors. ATG-017 is a potent and selective ERK1/2 inhibitor with best-in-class potential for the treatment of various hematological malignancies and solid tumors driven by the aberrant RAS/MAPK pathway. ATG-101 is a novel, PD-L1/CD137 (4-1BB) bi-specific antibody being developed for the treatment of hematological malignancies and solid tumors. ATG-037 is a highly potent, selective, orally-bioavailable small molecule inhibitor of CD73. It can reactivate antitumor immunity by inhibiting the highly immunosuppressive adenosine pathway.

Product Pipeline

We have a pipeline of 15 drug candidates that focus on oncology and range from pre-clinical stage to late-stage clinical programs. The following table summarizes our pipeline and the development status of each candidate in the regions noted in the chart below in the "Antengene Rights" column:



[1] (s)NDA approved by US FDA, Greater China (mainland China, Hong Kong, Taiwan), Australia, Singapore NDA submissions are completed; [2] Antengene has rights for Greater China (mainland China, Hong Kong, Taiwan, Macau), Australia, New Zealand, South Korea, and the ASEAN Countries; [3] Antengene has rights for Greater China, South Korea, Singapore, Malaysia, Indonesia, Vietnam, Laos, Cambodia, the Philippines, Thailand and Mongolia; [4] Licensed from AstraZeneca and Antengene has obtained exclusive global rights to develop, commercialize and manufacture ATG-017; [5] Licensed from Origincell and Antengene has obtained exclusive global rights to develop, commercialize and manufacture ATG-101; [6] Licensed from Calithera Biosciences and Antengene has obtained exclusive global rights to develop, commercialize and manufacture ATG-037; [7] Most advanced trial status in Antengene territories and the trials are responsible by Antengene; [8] Most advanced trial status in partner territories in the rest of the world and the trials are conducted by our licensing partners;

* Investigator-initiated trials; R/R = relapsed/refractory; ND = newly diagnosed; MDS = myelodysplastic syndrome; CRC = colorectal cancer; PrC = prostate cancer; CAEBV = chronic active Epstein-Barr virus; NHL = non-Hodgkin lymphoma; Hem/Onc = hematological malignancies and solid tumors; SK= South Korea; R-GDP: rituximab, gemcitabine, dexamethasone & cisplatin; ICE = Ifosfamide, carboplatin, and etoposide; GemOx = gemcitabine, oxaliplatin; in GBM-029 trial, the combination regimen is with standard of care (SoC) therapy for newly diagnosed glioblastoma or recurrent glioblastoma, including radiation therapy, temozolomide, lomustine, bevacizumab, tumor treating fields, or carmustine

BUSINESS REVIEW

We have made steady progress with regard to our pipeline assets in 2021 and submitted NDAs for selinexor in Australia, South Korea, Singapore, and Taiwan for the treatment of rrMM and rrDLBCL and in mainland China and Hong Kong for the treatment of rrMM. We have obtained NDA approvals in mainland China, Australia, South Korea and Singapore.

Late-stage Product Candidates

ATG-010 (selinexor, XPO1 inhibitor)

ATG-010 (selinexor), one of our Core Products, is a first-in-class, orally available SINE compound being developed for the treatment of various hematological malignancies and solid tumors. We obtained exclusive rights from Karyopharm for the development and commercialization of selinexor in mainland China, Hong Kong, Taiwan, Macau, South Korea, Australia, New Zealand and ASEAN countries.

Our licensing partner, Karyopharm, obtained approval through the U.S. FDA's Accelerated Approval Program on July 3, 2019 for XPOVIO® (selinexor) in combination with low-dose dexamethasone for the treatment of adult patients with rrMM who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents (IMiDs) and an anti-CD38 mAb.

On June 22, 2020, XPOVIO® (selinexor) received accelerated approval from the U.S. FDA for the treatment of adult patients with rrDLBCL, not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. On December 18, 2020, the U.S. FDA approved XPOVIO® (selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

In May 2021, Chinese Society of Clinical Oncology (CSCO) added multiple selinexor regimens to its 2021 Diagnosis and Treatment Guidelines for treatment of multiple myeloma and lymphoma.

In July 2021, through a priority review process, the MFDS of South Korea approved the Company's NDA for selinexor, in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody (penta-refractory); and as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma who have received at least two prior lines of treatment. In December 2021, we submitted supplemental sNDA to MFDS for selinexor in combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

In December 2021, selinexor received conditional approval for marketing by the NMPA, applicable in combination with dexamethasone for the treatment of adults with rrMM who have received prior therapy including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

Several late-stage clinical studies are underway for selinexor in mainland China:

A Phase II registrational clinical trial in combination with low-dose dexamethasone in rrMM (the "**MARCH**" trial). We submitted an NDA to the NMPA in mainland China in January 2021 and conditional approval was granted in December 2021.

A Phase II registrational clinical trial as monotherapy in rrDLBCL (the "**SEARCH**" trial). We dosed the first patient in SEARCH trial in 2020.

A Phase III registrational clinical trial in combination with bortezomib and low-dose dexamethasone in rrMM (the "**BENCH**" trial). We received IND approval from the NMPA at the end of 2020 and dosed the first patient in July 2021.

A Phase III registrational clinical trial as monotherapy as a maintenance therapy for patients with endometrial cancer, which is part of the global pivotal trial (the "**SIENDO**" trial) led by Karyopharm. We received IND approval from the NMPA in May 2021 and dosed the first patient in November 2021.

A Phase II/III registrational clinical trial in combination with rituximab, gemcitabine dexamethasone cisplatin ("**R-GDP**") in rrDLBCL, which is part of the global pivotal trial (XPORT-DLBCL-030) led by Karyopharm. We received IND approval from the NMPA in January 2021 and dosed the first patient in December 2021.

A Phase II registrational clinical trial as monotherapy for patients with myelofibrosis, which is part of the global pivotal trial (the "**MF 035**" trial) led by Karyopharm. We received IND approval from China NMPA in August 2021.

To further explore the clinical potential of selinexor in cancer treatment, we also initiated early signal detection studies including Phase Ib clinical trial in combination with ifosfamide, carboplatin and etoposide ("**ICE**") or gemcitabine and oxaliplatin ("**GemOx**") in the treatment of T-cell and NK/T-cell lymphoma patients, Phase Ib clinical trial in combination with ATG-008 (onatasertib) for the treatment of rrDLBCL and Phase I/II S-R^2 in rriNHL.

In March 2022, XPOVIO® (selinexor, ATG-010) has been granted approval from the Health Sciences Authority (HSA) in Singapore for three indications: in combination with bortezomib and dexamethasone for treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy; and in combination with dexamethasone for the treatment of adult patients with rrMM who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody (penta-refractory), and as a monotherapy for the treatment of adult patients with rrDLBCL who have received at least two prior lines of treatment and are not eligible for haematopoietic cell transplant.

In March 2022, Australia's Therapeutic Goods Administration (TGA) has registered XPOVIO® (selinexor, ATG-010) for two indications: (1) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy and (2) in combination with dexamethasone for the treatment of adult patients with rrMM who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor, at least one immunomodulatory medicinal product, and an anti-CD38 monoclonal antibody.

WE MAY NOT BE ABLE TO ULTIMATELY MARKET ATG-010 (SELINEXOR) SUCCESSFULLY.

ATG-008 (onatasertib, mTORC1/2 inhibitor)

ATG-008 (onatasertib), one of our Core Products. We obtained an exclusive license from Celgene for the development and commercialization of onatasertib in mainland China and selected APAC markets. In 2020, we continued to carry forward the clinical study in patients with HCC who received at least one line of prior therapy and dosed the first patient in cohort 3. In April 2021, we dosed the first patient in the fourth cohort of this study. We initiated a Phase I/II study of onatasertib in combination with toripalimab (anti-PD-1 antibody) in mainland China, and in February 2021, we dosed the first patient in the dose expansion cohort. A Phase II study in NFE2L2 mutant NSCLC is also ongoing in mainland China. In addition, we received IND approval from the NMPA for a Phase II biomarker driven solid tumor basket trial in August 2020, and we dosed the first patient in April 2021.

WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET ATG-008 (ONATASERTIB) SUCCESSFULLY.

Other Clinical Candidates

Eltanexor (ATG-016, second generation XPO1 inhibitor) – We obtained exclusive rights from Karyopharm for the development and commercialization of eltanexor in mainland China, Hong Kong, Taiwan, Macau, South Korea, Australia, New Zealand and ASEAN countries. In 2020, we obtained IND approval of a Phase I/II clinical study in patients with high-risk MDS from NMPA in mainland China, and in May 2021, we dosed the first patient. Subsequently, we received IND approval of a Phase I/II clinical study in patients with solid tumors from NMPA in mainland China in May 2021.

Verdinexor (ATG-527, third generation XPO1 inhibitor) – We obtained exclusive rights from Karyopharm for the development and commercialization of verdinexor in mainland China, Hong Kong, Taiwan, Macau, South Korea, Australia, New Zealand and ASEAN countries. Verdinexor will be developed in non-oncological indications. Having completed Phase I evaluation in healthy volunteers, a Phase II, multi-center, signal-seeking basket study protocol is now being developed in Australia that will evaluate the ability of verdinexor to suppress viral load across a range of chronic human viral infections.

ATG-019 (dual PAK4/NAMPT inhibitor) – We obtained exclusive rights from Karyopharm for the development and commercialization of ATG-019 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Australia, New Zealand and ASEAN countries. In 2020, we dosed the first patient in a Phase I solid tumor and lymphoma clinical study in Taiwan. Subsequently, we received IND approval from the NMPA in mainland China of a Phase I clinical trial to evaluate safety and tolerability of ATG-019 in patients with advanced solid tumors or non-Hodgkin's lymphoma in May 2021.

ATG-017 (ERK1/2 inhibitor) – We obtained exclusive rights from AstraZeneca AB ("**AstraZeneca**") for the development and commercialization of ATG-017 worldwide. In 2020, we dosed the first patient in a Phase I clinical study in Australia. The ongoing dose-escalation study of ATG-017 for the treatment of advanced solid tumors and hematologic malignancies in Australia (the ERASER trial).

ATG-101 (PD-L1/4-1BB bispecific antibody) – The Bellberry Human Research Ethics Committee (HREC) in Australia approved our clinical trial application ("**CTA**") of the Phase I trial of ATG-101 in patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma in July 2021. We also obtained IND clearance from the U.S. FDA in October for the PROBE study. In December 2021, we dosed the first patient in this trial in Australia. In March 2022, China NMPA approved the IND application for a Phase I study of ATG-101 in China.

Pre-clinical Candidates

ATG-037 (CD73 inhibitor) – the Bellberry Human Research Ethics Committee (HREC) in Australia approved our clinical trial application of the Phase I trial of ATG-037 in patients with locally advanced or metastatic solid tumors in February 2022. We plan to initiate this trial and start patient enrollment in Australia in the first half of 2022.

ATG-018 (ATR inhibitor) – We plan to submit the applications in the first half of 2022.

ATG-022 (Claudin 18.2 antibody-drug conjugate) – We are conducting preclinical studies to support IND/CTA applications of ATG-022 and plan to submit the applications in 2022.

ATG-012 (KRAS inhibitor) – We are conducting preclinical studies to support IND/CTA applications of ATG-012 and plan to submit the applications in 2023.

ATG-031 (CD24 antibody) – We are conducting preclinical studies to support IND/CTA applications of ATG-031 and plan to submit the applications in 2023.

ATG-027 (B7H3/PD-L1 bispecific antibody) – We are conducting preclinical studies to support IND/CTA applications of ATG-027 and plan to submit the applications in 2023.

ATG-032 (LILRB antibody) – We are conducting preclinical studies to support IND/CTA applications of ATG-032.

ATG-041 (Axl-Mer inhibitor) – We are conducting preclinical studies to support IND/CTA applications of ATG-041.

RESEARCH AND DEVELOPMENT

We focus on research and development of therapeutic strategies for the treatment of cancer. We seek to optimize the drug development process of each of our assets to fully unlock their therapeutic potential and maximise their clinical and commercial value. We have adopted a differentiated combinatory and complementary R&D approach to build a pipeline of first/best-in-class assets with synergistic profiles.

As at December 31, 2021, we have twenty-one ongoing clinical studies in mainland China, South Korea, Taiwan and Australia with six of our pipeline assets, including ATG-010 (selinexor, XPO1 inhibitor), ATG-008 (onatasertib, mTORC1/2 inhibitor), ATG-016 (eltanexor, XPO1 inhibitor), ATG-019 (dual PAK4/NAMPT inhibitor), ATG-017 (ERK1/2 inhibitor) and ATG-101 (PD-L1/4-1BB bispecific antibody). We have completed patient enrollment for the registrational Phase II clinical study (the "**MARCH**" trail), in patients with rrMM and are initiating and enrolling patients for five other registrational Phase II or Phase III studies in mainland China in rrMM, rrDLBCL, endometrial cancer and myelofibrosis, respectively. We also submitted NDA applications for ATG-010 (selinexor) to NMPA (mainland China), Therapeutic Goods Administration (Australia), MFDS (South Korea), Health Sciences Authority (Singapore), Hong Kong Department of Health, and TFDA (Taiwan). We have obtained NDA approvals in mainland China and South Korea as at December 31, 2021.

Our adjusted research and development costs (non-IFRS measure) were approximately RMB303.7 million and RMB382.7 million for the year ended December 31, 2020 and December 31, 2021 respectively. As at December 31, 2021, we had filed 3 patent applications in mainland China, and 4 international applications under the Patent Cooperation Treaty (PCT) for material intellectual properties, all of which are pending.

BUSINESS DEVELOPMENT

In May 2021, we entered into an exclusive, worldwide license agreement for the development and commercialization of CB-708 (ATG-037), Calithera Biosciences, Inc.'s small molecule inhibitor of CD73. Preclinical data presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting and the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting demonstrated that CB-708 has immune-mediated, single agent activity in syngeneic mouse tumor models. In preclinical studies, CB-708 was well-tolerated and had showed enhanced anti-tumor activity when combined with either an anti-PD-L1 immunotherapy or with chemotherapeutic agents, such as oxaliplatin or doxorubicin. CB-708 has completed GLP toxicology studies and is poised to advance into clinical development.

In October 2021, we entered into a Research Collaboration and License Option Agreement with LegoChem Biosciences, Inc. ("**LCB**", KOSDAQ: 141080) for new antibody-drug conjugates (ADCs). Under this agreement, the two parties will jointly generate and evaluate ADC candidates using Antengene's antibodies and LCB's next generation ADC technology platform. Antengene will have an exclusive option to license global rights for the development and commercialization of the resulting ADC candidates. When the option is exercised, LCB will be eligible to receive upfront and milestone payments, as well as tiered royalties. In addition, LCB is eligible to receive a prespecified percentage of any sublicensing income received by Antengene.

In December 2021, we entered into a R&D collaboration with XtalPi Inc, a quantum physics-based, AI-powered drug R&D company with the mission to revolutionize drug discovery and development by improving the speed, scale, novelty and success rate. Under terms of the agreement, XtalPi will utilize its integrated artificial intelligence (AI) research and development (R&D) platform comprised of proprietary cloud-supercomputer-powered in silico tools and its highly efficient wet lab to support Antengene's drug discovery and development programs.

In December 2021, we entered into a clinical trial collaboration to evaluate the safety, pharmacokinetics and preliminary efficacy of ATG-017 in combination with Bristol Myers Squibb's PD-1 checkpoint inhibitor, Opdivo® (nivolumab). The open-label Phase 1/2 trial will evaluate the investigational combination as a potential treatment option for patients with advanced solid tumors.

EVENTS AFTER THE REPORTING PERIOD

In January 2022, China NMPA accepted the IND application for a Phase 1/2 open label study designed to evaluate the safety, tolerability and efficacy of eltanexor in patients with newly diagnosed and relapsed/refractory cancer indications. Chinese sites will only participate in the Part F Phase 2 of this study to investigate eltanexor in high-risk MDS patients.

In February 2022, the Bellberry Human Research Ethics Committee (HREC) in Australia approved our clinical trial application of the Phase I trial of ATG-037 in patients with locally advanced or metastatic solid tumors. We plan to initiate this trial and start patient enrollment in Australia in the first half of 2022.

In March 2022, XPOVIO® (selinexor, ATG-010) has been granted approval from the HSA in Singapore for three indications: in combination with bortezomib and dexamethasone for treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy; and in combination with dexamethasone for the treatment of adult patients with rrMM who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody (penta-refractory), and as a monotherapy for the treatment of adult patients with rrDLBCL who have received at least two prior lines of treatment and are not eligible for haematopoietic cell transplant.

In March 2022, Australia's Therapeutic Goods Administration (TGA) has registered XPOVIO® (selinexor, ATG-010) for two indications: (1) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy and (2) in combination with dexamethasone for the treatment of adult patients with rrMM who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor, at least one immunomodulatory medicinal product, and an anti-CD38 monoclonal antibody.

In March 2022, China National Medical Products Administration (NMPA) has approved the Phase I study of ATG-101, a novel PD-L1/4-1BB bispecific antibody, (the PROBE-CN study) for the treatment of advanced/metastatic solid tumors and B-cell non-Hodgkin lymphoma (B-NHL). This open-label, multicenter Phase I study is designed to assess the safety and tolerability of intravenously administered ATG-101 monotherapy in patients with advanced/metastatic solid tumors and B-NHL.

FUTURE AND OUTLOOK

Leveraging our combinatory and complementary R&D strategy and through our strong R&D capabilities and strategic approach in developing novel therapies, we continue to realize our vision of treating patients beyond borders and improving their lives in discovering, developing and commercializing global first-in-class, only-in-class and/or best-in-class therapies.

We will continue to advance the clinical development of our eight clinical stage products in multiple therapeutic areas, and continue to implement our dual-engine approach of external partnerships and internal discovery to build up a pipeline focusing on the key oncogenic pathways, tumor microenvironment and tumor associated antigens globally and across the APAC region. We also intend to continue implementing our complementary approach to develop the in-licensed assets for additional indications to maximise their commercial potential.

We have received NDA approvals for XPOVIO® (selinexor, ATG-010) in mainland China and South Korea in 2021, and in Singapore and Australia in March 2022. Looking into 2022, we further expect to receive approvals for selinexor (ATG-010) in Hong Kong and Taiwan from the second quarter to the third quarter of 2022. We will also advance two of our pre-clinical novel assets into the IND stage.

With the expected NDA approvals mentioned above and building upon our core commercial leadership team with experience in multiple successful launches of top hematology products globally, in APAC region and China in the past, we will continue to build out our commercial team in preparation for a first-in-class launch of selinexor in Greater China and the rest of APAC region to address unmet medical needs in our territories. We expect to officially launch XPOVIO® (selinexor, ATG-010) in the second quarter of 2022 with strong KOL anticipation and support as another new innovative therapy for multiple hematological malignance with a unique mechanism of action.

During the Reporting Period, we have maintained a Named Patient Program (NPP) in Hong Kong and mainland China at the Boao Super Hospital in Boao Lecheng Pilot Zone (and has been authorized to be expanded beyond the Pilot Zone) for the treatment of patients with diseases including rrMM and rrDLBCL. The program has provided patients in Hong Kong and mainland China with unmet medical needs with access to an urgently needed therapy. The use of selinexor in such patients will also be a part of real-world research in APAC region.

FINANCIAL INFORMATION

The Board announces the consolidated results of the Group for the year ended December 31, 2021, with comparative figures for the corresponding period in the previous year as follows:

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

		Year ended December 31,	
		2021	2020
	Notes	***RMB'000***	*RMB'000*
REVENUE	*4*	**28,769**	–
Cost of sales		**(4,580)**	–
Gross profit		**24,189**	–
Other income and gains	*4*	**42,567**	26,834
Research and development costs		**(405,029)**	(347,655)
Selling and distribution expenses		**(67,941)**	(455)
Administrative expenses		**(169,463)**	(154,221)
Other expenses	*4*	**(79,154)**	(2,452,392)
Finance costs		**(698)**	(1,032)
LOSS BEFORE TAX	*5*	**(655,529)**	(2,928,921)
Income tax expense	*6*	**–**	–
LOSS FOR THE YEAR		**(655,529)**	(2,928,921)
Attributable to:			
Owners of the parent		**(655,529)**	(2,928,921)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	*8*		
Basic and diluted			
– For loss for the year		**RMB (1.05)**	RMB (11.66)

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Year ended December 31,	
	2021	2020
	RMB'000	*RMB'000*
LOSS FOR THE YEAR	**(655,529)**	(2,928,921)
OTHER COMPREHENSIVE INCOME		
Other comprehensive income that may be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of foreign operations	**16,039**	–
OTHER COMPREHENSIVE INCOME FOR THE YEAR, NET OF TAX	**16,039**	–
TOTAL COMPREHENSIVE LOSS FOR THE YEAR	**(639,490)**	(2,928,921)
Attributable to:		
Owners of the parent	**(639,490)**	(2,928,921)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	Notes	At December 31, 2021 **RMB'000**	2020 RMB'000
NON-CURRENT ASSETS			
Property, plant and equipment		**71,195**	56,233
Right-of-use assets		**14,916**	9,868
Other intangible assets		**3,539**	277
Equity investments designated at fair value through other comprehensive income		**2,574**	–
Financial assets at fair value through profit or loss		**4,195**	–
Prepayments and other receivables	*9*	**48,621**	–
Total non-current assets		**145,040**	66,378
CURRENT ASSETS			
Inventories		**2,578**	–
Trade receivables	*10*	**7,006**	–
Prepayments and other receivables	*9*	**32,495**	18,191
Financial assets at fair value through profit or loss		**95,737**	–
Cash and bank balances		**2,274,752**	3,109,832
Total current assets		**2,412,568**	3,128,023
CURRENT LIABILITIES			
Trade payables	*11*	**1,475**	–
Other payables and accruals	*12*	**147,008**	145,672
Lease liabilities		**10,879**	4,929
Total current liabilities		**159,362**	150,601
NET CURRENT ASSETS		**2,253,206**	2,977,422
TOTAL ASSETS LESS CURRENT LIABILITIES		**2,398,246**	3,043,800
NON-CURRENT LIABILITIES			
Lease liabilities		**3,933**	5,992
Total non-current liabilities		**3,933**	5,992
Net assets		**2,394,313**	3,037,808
EQUITY			
Equity attributable to owners of the parent			
Share capital		**446**	448
Treasury shares		**(18,758)**	(30)
Reserves		**2,412,625**	3,037,390
Total equity		**2,394,313**	3,037,808

NOTES TO THE FINANCIAL INFORMATION

1. CORPORATE AND GROUP INFORMATION

The Company is a limited liability company incorporated in the Cayman Islands on 28 August 2018. The registered address of the Company is the offices of Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.

The Company is an investing holding company. During the year, the Group was involved in the research and development of pharmaceutical products.

The shares of the Company have been listed on the Main Board of the Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") effective from 20 November 2020.

2.1 BASIS OF PREPARATION

These financial statements have been prepared in accordance with International Financial Reporting Standards ("**IFRSs**") (which include all International Financial Reporting Standards, International Accounting Standards ("**IASs**") and Interpretations) issued by the International Accounting Standards Board (the "**IASB**"), accounting principles generally accepted in Hong Kong and the disclosure requirements of the Hong Kong Companies Ordinance. They have been prepared under the historical cost convention, except for certain financial instruments which have been measured at fair value. These financial statements are presented in Renminbi ("**RMB**") and all values are rounded to the nearest thousand ("**RMB'000**") except when otherwise indicated.

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The Group has adopted the following revised IFRSs for the first time for the current year's financial statements.

Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16	*Interest Rate Benchmark Reform – Phase 2*
Amendment to IFRS 16	*Covid-19-Related Rent Concessions beyond 30 June 2021(early adopted)*

The adoption of the above amendments had no impact on the financial position and performance of the Group.

3. OPERATING SEGMENT INFORMATION

Operating segment information

For management purposes, the Group has only one reportable operating segment, which is the research and development of pharmaceutical products. Since this is the only reportable operating segment of the Group, no further operating segment analysis thereof is presented.

Geographical information

(a) Revenue from external customers

	2021	2020
	RMB'000	*RMB'000*
Greater China	**28,531**	–
Other countries/regions	**238**	–
	28,769	–

The revenue information above is based on the locations of the customers.

(b) Non-current assets

	2021 *RMB'000*	2020 *RMB'000*
Greater China	**137,164**	66,378
United States	**1,107**	–
	138,271	66,378

The non-current asset information above is based on the locations of the assets and excludes financial instruments.

Information about a major customer

Revenue from a single customer amounting to over 10% to the total revenue of the Group in the reporting period is as follows:

	2021 *RMB'000*	2020 *RMB'000*
Customer A	**28,315**	N/A

4. REVENUE, OTHER INCOME AND GAINS AND OTHER EXPENSES

An analysis of revenue is as follows:

	2021 *RMB'000*	2020 *RMB'000*
Revenue from contracts with customers	**28,769**	–

Revenue from contracts with customers

(a) Disaggregated revenue information

	2021 *RMB'000*	2020 *RMB'000*
Types of goods		
Sales of pharmaceutical products	**28,769**	–
Geographical markets		
Greater China	**28,531**	–
Other countries/regions	**238**	–
Total revenue from contracts with customers	**28,769**	–
Timing of revenue recognition		
Goods transferred at a point in time	**28,769**	–

(b) Performance obligations

Information about the Group's performance obligations is summarised below:

Sale of pharmaceutical products

The performance obligation is satisfied upon delivery of the pharmaceutical products and payment is generally due within 60 to 90 days from the billing date.

An analysis of other income and gains is as follows:

	2021	2020
	RMB'000	*RMB'000*
Other income		
Government grants related to income*	**23,970**	13,841
Bank interest income	**16,760**	12,202
Other interest income from financial assets at fair value through profit or loss	**1,072**	–
Others	**422**	747
	42,224	26,790
Other gains		
Fair value gain on financial assets at fair value through profit or loss	**343**	–
Gain on disposal of right-of-use assets for early terminated leases	**–**	44
	42,567	26,834

* Government grants include subsidies from the governments which are specifically for (i) the incentive and subsidies for research and development activities which are recognised upon compliance with the attached conditions; and (ii) other government grants related to income that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the Group with no future related costs recognised in profit or loss in the period in which they become receivable.

An analysis of other expenses is as follows:

	2021	2020
	RMB'000	*RMB'000*
Other expenses		
Fair value loss on convertible redeemable preferred shares	**–**	2,356,271
Foreign exchange loss, net	**77,750**	80,551
Loss on repurchase of convertible redeemable preferred shares	**–**	15,150
Others	**1,404**	420
	79,154	2,452,392

5. LOSS BEFORE TAX

The Group's loss before tax is arrived at after charging/(crediting):

	Notes	2021 RMB'000	2020 RMB'000
Cost of inventories sold		**4,580**	–
Depreciation of property, plant and equipment		**3,927**	390
Depreciation of right-of-use assets		**7,038**	3,648
Amortisation of other intangible assets		**532**	51
Lease payments not included in the measurement of lease liabilities		**508**	612
Auditor's remuneration		**2,300**	2,000
Share issue expenses		**–**	28,570
Employee benefit expense (excluding directors' and chief executive's remuneration):			
Wages and salaries		**131,711**	60,832
Pension scheme contributions (defined contribution scheme)		**16,227**	4,302
Staff welfare expenses		**5,913**	3,186
Equity-settled share option expense		**29,689**	2,259
		183,540	70,579
Foreign exchange differences, net*	*4*	**77,750**	80,551
Other interest income from financial assets at fair value through profit or loss**	*4*	**1,072**	–
Fair value gain on financial assets at fair value through profit or loss**	*4*	**343**	–
Loss on repurchase of convertible redeemable preferred shares*	*4*	**–**	15,150
Gain on disposal of right-of-use assets for early terminated leases**	*4*	**–**	(44)
Fair value loss on convertible redeemable preferred shares*		**–**	2,356,271

* Included in "Other expenses" in the consolidated statement of profit or loss

** Included in "Other income and gains" in the consolidated statement of profit or loss

6. INCOME TAX

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Cayman Islands

Under the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gains. In addition, upon payments of dividends by the Company to its shareholders, no Cayman Islands withholding tax is imposed.

British Virgin Islands

Under the current laws of the British Virgin Islands ("**BVI**"), the subsidiaries incorporated in the BVI are not subject to tax on income or capital gains. In addition, upon payments of dividends by these subsidiaries to their shareholders, no BVI withholding tax is imposed.

Hong Kong

The subsidiaries incorporated in Hong Kong were subject to income tax at the rate of 16.5% (2020: 16.5%) on the estimated assessable profits arising in Hong Kong during the year, except for one subsidiary of the Group which is a qualifying entity under the two-tiered profits tax rates regime. The first HK$2,000,000 (2020: HK$2,000,000) of assessable profits of this subsidiary are taxed at 8.25% (2020: 8.25%) and the remaining assessable profits are taxed at 16.5% (2020: 16.5%).

Macau

The subsidiary incorporated in Macau was subject to income tax at the rate of 12% (2020: 12%) on the estimated assessable profits arising in Macau during the year.

Mainland China

Pursuant to the Corporate Income Tax Law of the People's Republic of China and the respective regulations (the "**CIT Law**"), the subsidiaries which operate in Mainland China were subject to CIT at a rate of 25% (2020: 25%) on the taxable income.

Australia

No provision for Australia profits tax has been made as the Group had no assessable profits derived from or earned in Australia during the year (2020: Nil). The subsidiary incorporated in Australia was subject to income tax at the rate of 26% (2020: 26%) on the estimated assessable profits arising in Australia during the year.

Singapore

No provision for Singapore profits tax has been made as the Group had no assessable profits derived from or earned in Singapore during the year (2020: Nil). The subsidiary incorporated in Singapore was subject to income tax at the rate of 17% (2020: 17%) on the estimated assessable profits arising in Singapore during the year.

South Korea

No provision for South Korea profits tax has been made as the Group had no assessable profits derived from or earned in South Korea during the year. The subsidiary incorporated in South Korea was subject to income tax at the rate of 10% on the estimated assessable profits arising in South Korea during the year.

United States of America

The subsidiary incorporated in Delaware, the United States was subject to statutory federal corporate income tax of the United States at a rate of 21% (2020: 21%). It was also subject to the state income tax in Delaware at a rate of 8.7% (2020: 8.7%) during the year.

A reconciliation of the tax expense applicable to the loss before tax at the statutory rate for the country in which the Company and the majority of its subsidiaries are domiciled to the tax expense at the effective tax rate, and a reconciliation of the applicable rate (i.e., the statutory tax rate) to the effective tax rate, are as follows:

	2021	2020
	RMB'000	*RMB'000*
Loss before tax	**(655,529)**	(2,928,921)
Tax at the statutory tax rate (25%)	**(163,882)**	(732,230)
Different tax rates for specific jurisdictions or enacted by local authorities	**29,760**	48,764
Additional deductible allowance for qualified research and development costs	**(35,637)**	(17,951)
Expenses not deductible for tax	**14,306**	639,500
Tax losses and temporary differences not recognised	**155,453**	61,917
Tax charge at the Group's effective rate	**–**	–

The Group has accumulated tax losses in Mainland China of RMB828,955,000 and RMB346,330,000 as at 31 December 2021 and 2020, respectively, that will expire in one to five years for offsetting against future taxable profits of the companies in which the losses arose.

The Group also has accumulated tax losses in overseas subsidiaries of RMB220,008,000 and RMB45,172,000 in aggregate as at 31 December 2021 and 2020, respectively, that will be carried forward indefinitely for offsetting against future taxable profits of the companies in which the losses arose. Deferred tax assets have not been recognised in respect of these losses as they have arisen in subsidiaries that have been loss-making for some time and it is not considered probable that taxable profits in the foreseeable future will be available against which the tax losses can be utilised.

7. DIVIDENDS

No dividend was paid or declared by the Company during the years ended 31 December 2021 and 2020.

8. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic loss per share amounts is based on the loss for the year attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 624,989,465 shares (2020: 251,098,557 shares after adjusted for the effect of the capitalisation issue, as adjusted to reflect the rights issue in the year 2020) in issue.

No adjustment has been made to the basic loss per share amounts presented for the year ended 31 December 2021 in respect of a dilution as the impact of the share options (2020: the share options and redeemable convertible preferred shares) outstanding had an anti-dilutive effect on the basic loss per share amounts presented.

The calculations of basic and diluted loss per share are based on:

	2021	2020
	RMB'000	*RMB'000*
Loss		
Loss attributable to ordinary equity holders of the parent, used in the basic and diluted loss per share calculation	**(655,529)**	(2,928,921)

	Number of shares	
	2021	2020
Shares		
Weighted average number of ordinary shares in issue during the year used in the basic and diluted loss per share calculation	**624,989,465**	251,098,557

9. PREPAYMENTS AND OTHER RECEIVABLES

	2021	2020
	RMB'000	*RMB'000*
Non-current:		
Deposits and other receivables	**2,249**	–
Prepayments for purchases of property, plant and equipment	**3,262**	–
Prepayments for purchases of other intangible assets*	**43,110**	–
	48,621	–
Current:		
Value-added tax recoverable	**20,340**	11,478
Interest receivables	**7,409**	4,245
Amounts due from shareholders	**–**	37
Amounts due from related parties	**17**	17
Prepayments	**2,396**	718
Deposits and other receivables	**2,333**	1,696
	32,495	18,191

* It mainly represents prepayments for the purchase of the land for the construction of Hangzhou production base primarily for industrialisation of antibody drugs and research and development.

Other receivables had no historical default. The financial assets included in the above balances relate to receivables were categorised in stage 1 at the end of each reporting period. In calculating the expected credit loss rate, the Group considers the historical loss rate and adjusts for forward-looking macroeconomic data. During the year, the Group estimated that the expected credit loss rate for other receivables and deposits was minimal.

The balances are interest-free and are not secured with collateral.

The Group seeks to maintain strict control over its outstanding receivables to minimise credit risk. Long ageing balances are reviewed regularly by senior management. In view of the fact that the Group's deposits and other receivables relate to a large number of diversified counterparties, there is no significant concentration of credit risk. The Group does not hold any collateral or other credit enhancements over its deposits and other receivable balances.

10. TRADE RECEIVABLES

	2021 *RMB'000*	2020 *RMB'000*
Trade receivables	**7,008**	–
Impairment	**(2)**	–
	7,006	–

The Group's trading terms with its customers are mainly on credit. The credit period is generally two to three months. Each customer has a maximum credit limit. The Group seeks to maintain strict control over its outstanding receivables to minimize credit risk. Overdue balances are reviewed regularly by senior management. In view of the aforementioned and the fact that the Group's trade receivables relate to a large number of diversified customers, there is no significant concentration of credit risk. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. Trade receivables are non-interest-bearing.

An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	2021 *RMB'000*	2020 *RMB'000*
Within 3 months	**7,006**	–

The movements in the loss allowance for impairment of trade receivables are as follows:

	2021 *RMB'000*	2020 *RMB'000*
At beginning of year	**–**	–
Impairment losses	**2**	–
At end of year	**2**	–

An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on days past due for groupings of various customer segments with similar loss patterns by customer type and rating. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Generally, trade receivables are written off if past due for more than one year and are not subject to enforcement activity.

Set out below is the information about the credit risk exposure on the Group's trade receivables using a provision matrix:

As at 31 December 2021

	Current
Expected credit loss rate	**0.03%**
Gross carrying amount (RMB'000)	**7,008**
Expected credit losses (RMB'000)	**2**

11. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

	2021	2020
	RMB'000	*RMB'000*
Within 3 months	**1,475**	–

The trade payables are non-interest-bearing and are normally settled terms of two to three months.

12. OTHER PAYABLES AND ACCRUALS

	2021	2020
	RMB'000	RMB'000
Amounts due to related parties	**348**	16,545
Amounts due to shareholders	**–**	73
Deferred income*	**26,781**	36,381
Payroll payable	**40,446**	28,584
Other tax payables	**4,488**	3,113
Accrued share issue expenses	**3,692**	30,008
Payables for purchase of property, plant and equipment	**3,310**	4,548
Other payables**	**67,943**	26,420
	147,008	145,672

* During the year ended 31 December 2021, deferred income included the government grants related to an asset of RMB26,781,000 (2020: RMB26,781,000) that will be recognised in profit or loss over the expected useful life of the relevant asset. No (2020: RMB9,600,000) government grants related to income will be recognised in profit or loss upon the compliance of the Group with the conditions attached to the grants and the government acknowledges acceptance.

** Other payables primarily consist of accrued or invoiced but unpaid fees for service from contract research organisations ("CROs"), contract development manufacture organisations ("CDMOs") and clinical site management operators ("SMOs").

Other payables and accruals are unsecured, non-interest-bearing and repayable on demand. The carrying amounts of financial liabilities included in other payables and accruals as at the end of each reporting period approximate to their fair values due to their short-term maturities.

FINANCIAL REVIEW

	Year ended December 31,	
	2021	2020
	RMB'000	*RMB'000*
REVENUE	**28,769**	–
Cost of sales	**(4,580)**	–
Gross profit	**24,189**	–
Other income and gains	**42,567**	26,834
Research and development costs	**(405,029)**	(347,655)
Selling and distribution expenses	**(67,941)**	(455)
Administrative expenses	**(169,463)**	(154,221)
Other expenses	**(79,154)**	(2,452,392)
Finance costs	**(698)**	(1,032)
LOSS BEFORE TAX	**(655,529)**	(2,928,921)
Income tax expense	**–**	–
LOSS FOR THE YEAR	**(655,529)**	(2,928,921)
TOTAL COMPREHENSIVE LOSS FOR THE YEAR	**(639,490)**	(2,928,921)
Non-IFRS measures:		
Adjusted loss for the year	**(613,444)**	(454,958)

Revenue. Our revenue increased from nil for the year ended December 31, 2020 to RMB28.8 million for the year ended December 31, 2021, primarily attributable to the increase in revenue from our Named Patient Program.

Other Income and Gains. Our other income and gains increased by RMB15.8 million from RMB26.8 million for the year ended December 31, 2020 to RMB42.6 million for the year ended December 31, 2021, primarily attributable to the increase in government grants and bank interest income.

Other Expenses. Our other expenses decreased by RMB2,373.2 million from loss of RMB2,452.4 million for the year ended December 31, 2020 to loss of RMB79.2 million for year ended December 31, 2021. The decrease was mainly attributable to the absense of fair value loss on convertible redeemable preferred shares of RMB2,356.3 million as the Group had no preferred shares outstanding as at December 31, 2021.

Research and Development Costs. Our research and development costs increased by RMB57.3 million from RMB347.7 million for the year ended December 31, 2020 to RMB405.0 million for the year ended December 31, 2021. This increase was primarily attributable to the combined impact of (i) a slight decrease in employee costs of R&D personnel of RMB0.1 million from RMB89.2 million for the year ended December 31, 2020 to RMB89.1 million for the year ended December 31, 2021, mainly due to the decrease in equity-settled share option expense of RMB21.6 million from RMB43.9 million for the year ended December 31, 2020 to RMB22.3 million for the year ended December 31, 2021, which are partially offset by an increase in wages and salaries of R&D personnel of RMB17.0 million from RMB43.1 million for the year ended December 31, 2020 to RMB60.1 million for the year ended December 31, 2021 mainly due to our R&D headcount expansion; (ii) a decrease in licensing fees from RMB163.3 million for the year ended December 31, 2020 to RMB105.2 million for the year ended December 31, 2021 as we paid an upfront fee of RMB19.4 million in relation to our in-licensing in 2021, and made milestone payments of RMB63.1 million in relation to the Karyopharm Agreement and RMB22.7 million in relation to ATG-101, as compared to the licensing fees of RMB163.3 million for the year ended December 31, 2020; (iii) RMB111.1 million increase of our drug development expenses paid to contract research organisations ("**CRO(s)**"), contract development and manufacturing organisations ("**CDMO(s)**") and site management organisations ("**SMOs**") in line with our increased R&D activities.

	Year ended December 31,	
	2021	2020
	RMB'000	*RMB'000*
Employee costs		
Wages and salaries	**60,122**	43,064
Pension scheme contributions	**6,310**	2,197
Staff welfare expenses	**317**	7
Equity-settled share option expense	**22,313**	43,925
Depreciation and amortization	**2,325**	712
Licensing fees	**105,152**	163,266
Drug development expenses	**195,860**	84,783
Professional fees	**8,614**	8,312
Others	**4,016**	1,389
Total	**405,029**	347,655

Selling and distribution expenses. Our selling and distribution expenses increased by RMB67.4 million from RMB0.5 million for the year ended December 31, 2020 to RMB67.9 million for the year ended December 31, 2021, primarily attributable to the increase in employee costs and professional fees incurred for activities associated with marketing and sales related to preparations to commercialize our lead product, selinexor, in Greater China and other countries/regions.

	Year ended December 31,	
	2021	2020
	RMB'000	*RMB'000*
Employee costs		
Wages and salaries	**29,053**	–
Pension scheme contributions	**4,966**	–
Staff welfare expenses	**497**	–
Equity-settled share option expense	**2,039**	–
Professional fees	**16,013**	–
Depreciation and amortization	**3,260**	–
Others	**12,113**	455
Total	**67,941**	455

Administrative Expenses. Our administrative expenses increased by RMB15.3 million from RMB154.2 million for the year ended December 31, 2020 to RMB169.5 million for the year ended December 31, 2021. This increase was primarily attributable to (i) an increase in employee costs of administrative personnel of RMB5.5 million from RMB83.6 million for the year ended December 31, 2020 to RMB89.1 million for the year ended December 31, 2021, mainly due to an increase in wages and salaries of administrative personnel of RMB28.1 million from RMB32.1 million for the year ended December 31, 2020 to RMB60.2 million for the year ended December 31, 2021, which are partially offset by the decrease of share-based payments charged to administrative expenses of RMB27.5 million; and (ii) RMB30.4 million increase in professional fees for legal, consulting, recruiting, translation and other services in relation to operating and administrative activities; and (iii) RMB28.6 million decrease of listing expenses since we did not incur such expenses in relation to the IPO for year ended December 31, 2021.

	Year ended December 31,	
	2021	2020
	RMB'000	*RMB'000*
Employee costs		
Wages and salaries	**60,201**	32,124
Pension scheme contributions	**6,069**	3,074
Staff welfare expenses	**5,097**	3,179
Equity-settled share option expense	**17,733**	45,197
Listing expenses	**–**	28,570
Professional fees	**46,744**	16,308
Depreciation and amortization	**5,912**	3,377
Others	**27,707**	22,392
Total	**169,463**	154,221

Finance Costs. Our finance costs decreased slightly by RMB0.3 million from RMB1.0 million for the year ended December 31, 2020 to RMB0.7 million for the year ended December 31, 2021. This decrease was primarily attributable to decrease in the interest expenses on lease liabilities.

Non-IFRS Measures

To supplement the Group's consolidated financial statements, which are presented in accordance with the IFRS, the Company also uses adjusted loss for the year and other adjusted figures as additional financial measures, which are not required by, or presented in accordance with, the IFRS. The Company believes that these adjusted measures provide useful information to shareholders and potential investors in understanding and evaluating the Group's consolidated results of operations in the same manner as they help the Company's management.

Adjusted loss for the year represents the loss for the year excluding the effect of equity-settled share option expense, share issue expenses and certain non-cash items and one-time events, namely fair value loss on convertible redeemable preferred shares. The term adjusted loss for the year is not defined under the IFRS. The use of this non-IFRS measure has limitations as an analytical tool, and you should not consider it in isolation from, or as substitute for analysis of, the Group's results of operations or financial condition as reported under IFRS. The Company's presentation of such adjusted figure may not be comparable to a similarly titled measure presented by other companies. However, the Company believes that this and other non-IFRS measures are reflections of the Group's normal operating results by eliminating potential impacts of items that the management do not consider to be indicative of the Group's operating performance, and thus, facilitate comparisons of operating performance from period to period and company to company to the extent applicable.

The table below sets forth a reconciliation of the loss to adjusted loss during the years indicated:

	Year ended December 31	
	2021	2020
	RMB'000	*RMB'000*
Loss for the year	**(655,529)**	(2,928,921)
Added:		
Fair value loss on convertible redeemable preferred shares	**–**	2,356,271
Share issue expenses	**–**	28,570
Equity-settled share option expense	**42,085**	89,122
Adjusted loss for the year	**(613,444)**	(454,958)

Employees and Remuneration Policies

The following table sets forth a breakdown of our employees as at December 31, 2021 by function:

Function	Number of employees	% of total number of employees
G&A	55	16.72
Research and Development	101	30.69
Commercialization	154	46.81
Manufacturing	19	5.78
Total	329	100.00

As at December 31, 2021, we had 293 employees in China and 36 employees in overseas. Our employees' remuneration comprises salaries, bonuses, employee provident fund and social security contributions and other welfare payments. In accordance with applicable Chinese laws, we have made contributions to social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds for our employees.

Liquidity and Financial Resources

As at December 31, 2021, our cash and bank balances were RMB2,274.8 million, as compared to RMB3,109.8 million as at December 31, 2020. The decrease was mainly due to expenses of operating activities and funds used in investing and financing activities.

As at December 31, 2021, the Group's cash and bank balances were held mainly in USD and RMB.

As at December 31, 2021, the current assets of the Group were RMB2,412.6 million, including cash and bank balances of RMB2,274.8 million, financial assets at fair value through profit or loss of RMB95.7 million and other current assets of RMB42.1 million. As at December 31, 2021, the current liabilities of the Group were RMB159.4 million, including other payables and accruals of RMB147.0 million and other current liabilities of RMB12.4 million.

As at December 31, 2021, the financial assets at fair value through profit or loss in current assets represented our investments in wealth management products as part of our cash management.

Current ratio

Current ratio is calculated using current assets divided by current liabilities and multiplied by 100%. As at December 31, 2021, our current ratio was 1,513.9% (as at December 31, 2020: 2,077.0%).

Gearing Ratio

Gearing ratio is calculated using total liabilities divided by total assets and multiplied by 100%. As at December 31, 2021, our gearing ratio was 6.4% (as at December 31, 2020: 4.9%).

Other Financial Information

Significant Investments, Material Acquisitions and Disposals

As at December 31, 2021, we did not hold any significant investments. For the year ended December 31, 2021, we did not have material acquisitions or disposals of subsidiaries, associates and joint ventures.

Future Plans for Material Investments or Capital Assets

Save as the transactions contemplated under the framework agreement with Qiantang New Area Administrative Committee as disclosed in page 9 of this announcement, we did not have any other concrete plans for material investments or capital assets for the year of 2022 as at December 31, 2021.

Foreign Exchange Risk

We have transactional currency exposures. The majority of our bank balances and interest receivables are denominated in foreign currencies and are exposed to foreign currency risk. We currently do not have a foreign currency hedging policy. However, the management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

Contingent Liabilities

As at December 31, 2021, we did not have any material contingent liabilities.

Pledge of assets

There was no pledge of the Group's assets as at December 31, 2021.

CORPORATE GOVERNANCE AND OTHER INFORMATION

Compliance with the Corporate Governance Code

The Company is committed to maintain high standards of corporate governance to safeguard the interests of the shareholders and to enhance corporate value and accountability. The Company has applied the principles and code provisions as set out in the Corporate Governance Code and Corporate Governance Report (the "**CG Code**") contained in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("**Listing Rules**"). During the year ended December 31, 2021, the Board is of the opinion that the Company has complied with all the code provisions apart from the deviation below.

Code provision C.2.1 (former code provision A.2.1) of the CG Code provides that the roles of the chairman of the Board (the "**Chairman**") and chief executive officer ("**CEO**") should be separated and should not be performed by the same individual. During the year ended December 31, 2021 and as at the date of this announcement, the roles of the Chairman and CEO of the Company are held by Dr. Jay Mei ("**Dr. Mei**") who is a founder of the Company.

The Board believes that, in view of his experience, personal profile and his roles in the Company, Dr. Mei is the director best suited to identify strategic opportunities and focus of the Board due to his extensive understanding of our business as the CEO. The Board also believes that the combined role of Chairman and CEO can promote the effective execution of strategic initiatives and facilitate the flow of information between management and the Board.

Further, the decisions to be made by the Board require approval by at least a majority of our directors and that the Board comprises two non-executive directors and three independent non-executive directors, which the Company believes that there are sufficient checks and balances in the Board. Dr. Mei and other Directors are aware of and undertake to fulfill their fiduciary duties as Directors, which require, among other things, that they shall act for the benefit and in the best interest of the Company and will make decisions for the Group accordingly.

The Board will continue to review and consider splitting the roles of the Chairman and the CEO at the time when it is appropriate by taking into account the circumstances of the Group as a whole. Further information concerning the corporate governance practices of the Company will be set out in the corporate governance report in the annual report of the Company for the year ending December 31, 2021.

The Company will continue to regularly review and monitor its corporate governance practices to ensure compliance with the CG Code, and maintain a high standard of corporate governance practices of the Company.

Model Code for Securities Transactions by Directors of Listed Issuers

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix 10 to the Listing Rules (the "**Model Code**").

Specific enquiries have been made of all the Directors and they have confirmed that they have complied with the Model Code throughout the Reporting Period.

The Company's employees, who are likely to be in possession of unpublished inside information of the Company, are subject to the Model Code. No incident of non-compliance of the Model Code by the employees was noted by the Company throughout the Reporting Period.

Purchase, Sale or Redemption of Listed Securities

During the Reporting Period, the Company repurchased 5,497,500 shares on the Stock Exchange for an aggregate consideration of approximately HK$58.3 million before expenses. All of the repurchased shares were subsequently cancelled. Details of the share repurchased are as follows:

Month of Repurchase during the Reporting Period	No. of Shares Repurchased	Price paid per share		Aggregate consideration paid *(HK$)*
		Highest price paid *(HK$)*	Lowest price paid *(HK$)*	
October 2021	1,446,000	11.16	10.16	15,173,560
November 2021	1,844,500	12.48	10.12	20,165,550
December 2021	2,207,000	11.9	9.54	22,915,575
Total	5,497,500			58,254,685

Subsequent to the Reporting Period, in January 2022 the Company repurchased 1,300,000 shares on the Stock Exchange for an aggregate consideration of approximately HK$12.0 million before expenses. The highest price paid per share and the lowest price paid per share is HK$9.61 and HK$9.07 respectively.

Save as disclosed above, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's securities listed on the Stock Exchange during the Reporting Period and up to the date of this announcement.

Use of Net Proceeds

The shares of the Company were listed on the Main Board of the Stock Exchange on November 20, 2020 (the "**Listing Date**"). The Group received net proceeds (after deduction of underwriting commissions and related costs and expenses) from the IPO and the exercise of over-allotment option of approximately RMB2,274.70 million.

The net proceeds from the listing (adjusted on a pro rata basis based on the actual net proceeds) have been and will be utilized in accordance with the purposes set out in the prospectus of the Company dated November 9, 2020. The table below sets out the planned allocations of the net proceeds and actual usage up to December 31, 2021:

Function	**% of use of proceeds (Approximately)**	**Net proceeds from the HK IPO** *RMB million*	**Actual usage up to December 31, 2021** *RMB million*	**Unutilized net proceeds as at December 31, 2021** *RMB million*
Fund ongoing and planned clinical trials and milestone payments of our two Core Products and commercial launches of ATG-010	41%	932.63	340.17	592.46
Fund ongoing and planned clinical trials and milestone payments of four other clinical-stage drug candidates in our pipeline	25%	568.67	44.59	524.08
Fund ongoing pre-clinical studies and planned clinical trials for other pre-clinical drug candidates in our pipeline	9%	204.72	146.42	58.30
For expansion of our pipeline, including discovery of new drug candidates and business development activities	14%	318.46	31.98	286.48
For capital expenditure	1%	22.75	22.75	–
For general corporate purposes	10%	227.47	170.33	57.14
Total	100%	2,274.70	756.24	1,518.46

Notes:

(a) Net proceeds from the IPO were received in HKD and translated into RMB for the allocation and the utilization calculation, and have been adjusted slightly due to the fluctuation of the foreign exchange rates since the listing.

(b) The unutilized net proceeds of RMB1,518.46 million as at December 31, 2021 are expected to be completely used by December 31, 2024.

Audit Committee

The audit committee of the Company (the "**Audit Committee**") has three members (who are all independent non-executive directors), being Mr. Sheng Tang (chairman), Mr. Mark J. Alles, and Ms. Jing Qian with terms of reference in compliance with the Listing Rules.

The Audit Committee has considered and reviewed the accounting principles and practices adopted by the Group and discussed matters in relation to internal control and financial reporting with the management. The Audit Committee reviewed and considered that the annual financial results for the year ended December 31, 2021 are in compliance with the relevant accounting standards, rules and regulations and appropriate disclosures have been duly made.

Scope of work of Ernst & Young

The figures in respect of the Group's consolidated statement of financial position, consolidated statement of profit or loss and consolidated statement of comprehensive income and the related notes thereto for the year ended December 31, 2021 as set out in the preliminary announcement have been agreed by the Group's auditor, Ernst & Young, to the amounts set out in the Group's audited consolidated financial statements for the year. The work performed by Ernst & Young in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and consequently no assurance has been expressed by Ernst & Young on this announcement.

Material Litigation

The Company was not involved in any material litigation or arbitration during the year ended December 31, 2021. The Directors are also not aware of any material litigation or claims that are pending or threatened against the Group as at December 31, 2021.

PUBLIC FLOAT

According to the information that is publicly available to the Company and within the knowledge of the Board, at least 25% of the Company's total issued share capital was held by the public at all times since the Listing Date and up to December 31, 2021 as required under the Listing Rules.

FINAL DIVIDEND

The Board does not recommend the payment of a dividend for the year ended December 31, 2021.

ANNUAL GENERAL MEETING

The annual general meeting is scheduled to be held on June 1, 2022 (the "**AGM**"). A notice convening the AGM will be published and dispatched to the shareholders of the Company in the manner required by the Listing Rules in due course.

CLOSURE OF THE REGISTER OF MEMBERS

The register of members of the Company will be closed from Friday, May 27, 2022 to Wednesday, June 1, 2022, both days inclusive, in order to determine the identity of the shareholders who are entitled to attend and vote at the AGM, during which period no share transfers will be registered. To be eligible to attend and vote at the AGM, unregistered holders of shares must lodge all properly completed transfer forms accompanied by the relevant share certificates with the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration not later than 4:30 p.m. on Thursday, May 26, 2022.

PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT AND ANNUAL REPORT

This announcement is published on the websites of the Stock Exchange (**www.hkexnews.hk**) and the Company (**www.antengene.com**).

The annual report for the year ended December 31, 2021 containing all the information required by Appendix 16 to the Listing Rules will be dispatched to shareholders and published on the websites of the Stock Exchange and the Company in April 2022.

APPRECIATION

The Board would like to express its sincere gratitude to the shareholders, management team, employees, business partners and customers of the Group for their support and contribution to the Group.

By order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, March 18, 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. Jay Mei, Mr. John F. Chin, Dr. Kevin Patrick. Lynch and Mr. Donald Andrew Lung as executive directors; Mr. Liu Yilun and Dr. Kan Chen as non-executive directors; and Mr. Mark J. Alles, Ms. Jing Qian and Mr. Sheng Tang as independent non-executive directors.